AN APPLICATION to the US Food and Drug Administration by AFT Pharmaceuticals for registration of Maxigesic tablets has been accepted, with the company saying it's a "significant milestone in getting Maxigesic into the key US market".
Other key drivers for the product will include the 01 Feb 2018 rescheduling of codeine in Australia and possibly a similar proposal under consideration in NZ.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 May 17